💸 The Tape

When lawmakers talk about cannabis safety, the conversation almost always starts and ends in the same place: enforcement. Raid the smoke shops, ban the hemp-derived products, crack down on the gray market, and declare victory. It's a tidy narrative. It's also, according to the people actually consuming these products, largely beside the point.

The latest Dales Report x NuggMD Cannabis Consumer Poll, conducted August 14–17, 2026 among 513 verified consumers in state-legal markets, asked a deceptively simple question: if you could fix one thing about cannabis safety, what would it be? The answers should force a rethink in every statehouse currently drafting its next hemp ban.

The Numbers Tell a Different Story

Only 13% of respondents chose "cracking down on unregulated products" as their top safety priority. Read that again. The policy lever that consumes the overwhelming majority of regulatory attention and enforcement budgets ranked dead last among consumers' actual concerns.

What topped the list instead? Stronger testing standards, at a commanding 40%. Another 26% prioritized clearer education on products and dosing, and 21% wanted easier, more affordable access to licensed retail. Add those up and 87% of consumers are essentially saying the same thing: don't just take the bad products away — make the good products better, cheaper, easier to find, and easier to understand.

This is not consumers shrugging at the illicit market. It's consumers telling regulators that prohibition-by-another-name is a supply-side answer to a demand-side problem.

Testing Is the Trust Deficit Nobody Has Fixed

The 40% who chose testing standards aren't being paranoid — they're being observant. A March 2025 NuggMD poll found that only 32% of consumers had high confidence their cannabis was free of contaminants. That means two-thirds of people in legal markets are lighting up with their fingers crossed.

And the unregulated side is measurably worse. NuggMD's 2024 investigative testing of products purchased from unlicensed California shops found that 75% failed contamination testing. Three out of four. That's not a quality control problem; that's a public health experiment running without consent forms.

Here's the irony worth sitting with: the unsafe conditions prohibitionists spent decades warning would come from state-licensed cannabis programs have instead materialized in the unregulated hemp market — a market that exists largely because overregulation, high taxes, and sparse licensed retail pushed consumers toward the path of least resistance. The intoxicating hemp boom didn't happen despite regulation. In many ways, it happened because of it.

Bans Don't Erase Demand — They Redirect It

If there's one throughline in NuggMD's polling over the past two years, it's this: consumers are pragmatists. An August 2024 poll found 82% of consumers had little or no trust in unregulated products — yet many kept buying them anyway, because trust is a luxury and access is a necessity.

The instructive data point comes from July 2026, when NuggMD polled consumers in a market that had just enacted a local hemp ban. More than 56% of respondents reported either getting their medical card or switching to licensed dispensaries in response. On its face, that looks like a win for the ban-first crowd. But look closer: those consumers didn't migrate to the licensed market because the ban made them safety-conscious. They migrated because a licensed alternative existed and was reachable. A ban in a state with three dispensaries and a six-week card approval process produces a very different migration pattern — one that flows straight back underground.

The lesson for regulators is that a crackdown only works as the second half of a policy. The first half is building a regulated market people can actually get into. Bans without access are just prohibition with extra paperwork.

The Education Gap Is a Policy Choice

The 26% who prioritized clearer education on products and dosing are pointing at something regulators rarely acknowledge: the information vacuum is largely self-inflicted. Licensed cannabis brands operate under advertising and social media restrictions so severe that answering a basic dosing question online can risk a platform ban or regulatory reprisal. Meanwhile, the unregulated market faces no such constraints and fills the void with whatever marketing it pleases.

Think about that asymmetry. The companies with tested, labeled, traceable products are muzzled, while the companies selling mystery gummies from a gas station counter have free rein. If a policy framework were deliberately designed to keep consumers uninformed, it would look remarkably like the current one. Allowing legitimate brands to discuss their products openly — potency, onset times, interactions, dosing guidance — isn't a marketing giveaway. It's harm reduction.

What a Consumer-First Safety Agenda Looks Like

Put the pieces together and the poll sketches a clear roadmap for any regulator who wants to demonstrate — rather than merely announce — a commitment to consumer safety:

First, strengthen and standardize testing in the regulated market, and make the results legible to consumers. Trust is built at the lab, not the press conference.

Second, expand access. That means more licensed retail, lower compliance costs that get passed through to shelf prices, and streamlined pathways connecting patients with qualified doctors and pharmacists. Every barrier between a consumer and a licensed dispensary is a subsidy for the unregulated market.

Third, let legal brands communicate. Education can't come exclusively from a compliance-approved pamphlet nobody reads.

Fourth — and only fourth — enforce against bad actors, once the legal market is genuinely competitive on price, convenience, and information.

The Bottom Line

The margin of error on this poll is ±4.33%, but the directional message doesn't need fine print. Consumers aren't asking for a war on unregulated products. They're asking for a regulated market worth choosing — one that's tested, affordable, accessible, and honest with them. The 13% figure isn't consumer apathy about the illicit market. It's a verdict on enforcement-first policymaking: consumers have watched the crackdown approach for years, and they've concluded the real safety gains live elsewhere.

Regulators who ban hemp without expanding the legal alternative aren't eliminating demand. They're just choosing not to see where it goes next.

📈 Dog Walkers

$CWBHF ( ▲ 1.35% ) A Match Made In CBD Heaven

With a federal hemp ban looming in November, the industry's responsible operators are doing two things at once: consolidating and lobbying. The latest example checks both boxes.

Charlotte's Web Holdings (TSX: CWEB) (OTCQX: CWBHF) has announced a strategic partnership with Edibles.com, putting the hemp wellness pioneer's best-selling products on the retailer's online marketplace and in its flagship Atlanta store. The lineup includes hemp extracts for sleep, focus, and everyday wellness, functional mushroom offerings, and a topical cream for targeted relief.

But the commercial deal is arguably the undercard. The main event is political: both companies are jointly urging Congress to act before the November 12, 2026 deadline — either by redefining non-intoxicating hemp or extending the recriminalization measures set to take effect this fall.

There's real momentum on that front. On August 8, the U.S. Senate passed a Continuing Resolution including a 30-day extension that would allow the sale of naturally derived hemp products through December 11, 2026. If the House approves and the President signs, lawmakers buy themselves time to hammer out a targeted framework — and eventually a comprehensive regulatory solution — for hemp-derived products.

The consumer case for getting this right is straightforward. According to Brightfield Group, 93.8% of CBD consumers use hemp products to support more than one health need, and 57.8% regularly incorporate full-spectrum hemp into their wellness routines — with pain management, sleep, and stress relief leading the way.

Both companies are leaning into the same positioning: health, not high. "The conversation has evolved," said Edibles.com president Thomas Winstanley, noting the industry is no longer debating whether guardrails are needed — it's helping define what they should look like.

Charlotte's Web CEO Bill Morachnick was even more direct, calling the partnership "a signal of where the American hemp industry is headed" and arguing that responsible companies have paid the price for a market without clear rules for too long. His pitch to Washington: bring transparency and pragmatism to the industry while preserving safe access for everyday Americans.

The immediate ask is simple — both companies want the House to vote in favor of extending the November ban when Congress returns in September, giving lawmakers runway to turn bipartisan progress into lasting policy.

In an industry long defined by regulatory gray areas, two brands betting their futures on clear rules is a story worth watching.

📺 Trade To Black

Psychedelics Get Federal Attention, CBD Program Update | TTB Presented by Flowhub

• SAMHSA drops new federal guidance on psychedelics: The agency is telling states to prepare now for potential FDA approval of psilocybin and MDMA — flagging Medicaid coverage, oversight frameworks, and state-federal legal conflicts as issues to solve before approval, not after.

• Matthew "Whiz" Buckley joins the show: The Top Gun Options founder, former fighter pilot, and longtime psychedelic investing voice breaks down what the report means for the industry and where regulation heads next.

• NuggMD Check-In Poll of the Week: 513 respondents named the one thing they'd fix about cannabis safety — with cracking down on unregulated products and stronger testing standards emerging as the top priorities.

• Vantage Standard segment: Dr. Paul Shields, Chief Medical Officer at Vantage Hemp, gives an update on the CBD pilot program — why progress has lagged and what it will take to get it moving.